Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 14.19 Million EUR | 0.0% |
| 2022 | - EUR | 0.0% |
| 2021 | - EUR | 0.0% |
| 2020 | - EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.1 Million EUR | 0.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - EUR | 0.0% |
| 2023 FY | - EUR | 0.0% |
| 2023 Q3 | - EUR | 0.0% |
| 2023 Q2 | - EUR | 0.0% |
| 2023 Q1 | - EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | - EUR | 0.0% |
| 2021 FY | - EUR | 0.0% |
| 2020 FY | - EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -205.854% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -207.111% |
| Adocia SA | 2.15 Million EUR | -560.075% |
| Aelis Farma SA | 9.05 Million EUR | -56.744% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -350.384% |
| genOway Société anonyme | 20.04 Million EUR | 29.206% |
| IntegraGen SA | 12.53 Million EUR | -13.194% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -4630.001% |
| Neovacs S.A. | 533.41 Thousand EUR | -2560.535% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -743.978% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -71589.291% |
| Sensorion SA | 4.74 Million EUR | -199.208% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -4689.108% |
| TME Pharma N.V. | 17 Thousand EUR | -83380.071% |
| Valbiotis SA | 4.73 Million EUR | -199.844% |
| TheraVet SA | 1.07 Million EUR | -1216.409% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -688.423% |
| argenx SE | 1.13 Billion EUR | 98.749% |
| BioSenic S.A. | 543 Thousand EUR | -2513.557% |
| Celyad Oncology SA | 102 Thousand EUR | -13813.345% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 94.08% |
| Genfit S.A. | 28.56 Million EUR | 50.318% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -580.001% |
| Innate Pharma S.A. | 51.9 Million EUR | 72.656% |
| Inventiva S.A. | 17.47 Million EUR | 18.798% |
| MaaT Pharma SA | 2.22 Million EUR | -536.966% |
| MedinCell S.A. | 9.16 Million EUR | -54.93% |
| Nanobiotix S.A. | 30.05 Million EUR | 52.786% |
| Onward Medical N.V. | 532 Thousand EUR | -2567.596% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -537.252% |
| Oxurion NV | 263 Thousand EUR | -5296.05% |
| Pharming Group N.V. | 245.31 Million EUR | 94.215% |
| Poxel S.A. | 1.98 Million EUR | -616.386% |
| GenSight Biologics S.A. | 1.26 Million EUR | -1020.096% |
| Transgene SA | 1.18 Million EUR | -1098.616% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.73% |
| Valneva SE | 153.71 Million EUR | 90.767% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 492.033% |